Coca-Cola Europacific Partners Plc (CCEP) concluded trading on Wednesday at a closing price of $85.68, with 2.28 million shares of worth about $195.14 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 4.64% during that period and on Wednesday the price saw a gain of about 0.11%. Currently the company’s common shares owned by public are about 474.92M shares, out of which, 215.08M shares are available for trading.
Stock saw a price change of 3.33% in past 5 days and over the past one month there was a price change of -1.22%. Year-to-date (YTD), CCEP shares are showing a performance of 11.55% which increased to 20.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $65.94 but also hit the highest price of $88.39 during that period. The average intraday trading volume for Coca-Cola Europacific Partners Plc shares is 1.96 million. The stock is currently trading 0.78% above its 20-day simple moving average (SMA20), while that difference is up 5.55% for SMA50 and it goes to 10.24% higher than SMA200.
Coca-Cola Europacific Partners Plc (NASDAQ: CCEP) currently have 474.92M outstanding shares and institutions hold larger chunk of about 33.45% of that.
The stock has a current market capitalization of $39.44B and its 3Y-monthly beta is at 0.71. PE ratio of stock for trailing 12 months is 25.71, while it has posted earnings per share of $3.33 in the same period. Its PEG reads 2.96 and has Quick Ratio of 0.62 while making debt-to-equity ratio of 1.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CCEP, volatility over the week remained 1.55% while standing at 1.95% over the month.
Stock’s fiscal year EPS is expected to rise by 7.16% while it is estimated to increase by 8.41% in next year. EPS is likely to grow at an annualized rate of 8.69% for next 5-years, compared to annual growth of 4.96% made by the stock over the past 5-years.
On December 03, 2024, Bernstein Initiated their recommendations, while on November 27, 2024, JP Morgan Downgrade their ratings for the stock with a price target of $82. Stock get a Neutral rating from Exane BNP Paribas on September 10, 2024.
